Peripheral Neuropathy: Nerve Damage and Its Causes

Peripheral neuropathy describes damage to the peripheral nervous system — the network of nerves that relays signals between the brain and spinal cord and the rest of the body. The condition affects an estimated 20 million people in the United States, according to the National Institute of Neurological Disorders and Stroke (NINDS). Understanding the underlying causes, nerve fiber classifications, and diagnostic thresholds is essential for distinguishing peripheral neuropathy from overlapping neurological conditions covered across neurologicalauthority.com.

Definition and Scope

Peripheral neuropathy is not a single disease but a broad category encompassing more than 100 distinct conditions, as catalogued by NINDS. Damage may involve a single nerve (mononeuropathy), two or more nerves in separate areas (multiple mononeuropathy), or widespread nerve involvement throughout the body (polyneuropathy).

The peripheral nervous system divides functionally into three major nerve types:

• Sensory nerves — transmit signals for touch, temperature, vibration, and pain
• Motor nerves — carry commands from the brain to muscles
• Autonomic nerves — regulate involuntary functions including heart rate, digestion, and bladder control

Damage to each type produces distinct symptom profiles. Sensory nerve damage typically causes numbness, tingling, or burning pain. Motor nerve involvement leads to muscle weakness or paralysis. Autonomic nerve damage can produce blood pressure instability, abnormal sweating, and gastrointestinal dysfunction.

The International Classification of Diseases, 11th Revision (ICD-11), published by the World Health Organization, classifies peripheral neuropathies under Chapter 8 (Diseases of the Nervous System), with specific codes distinguishing hereditary, inflammatory, and acquired subtypes — a schema that directly informs billing, research registries, and clinical trial enrollment criteria.

How It Works

Peripheral nerve damage operates through four primary pathological mechanisms, each producing measurable structural changes:

1. Axonal degeneration — The axon itself deteriorates while the myelin sheath may remain intact. Electrophysiologically, this pattern shows reduced amplitude on nerve conduction studies (EMG and nerve conduction studies) with relatively preserved conduction velocity.
2. Demyelination — The protective myelin sheath breaks down, slowing or blocking electrical conduction. Nerve conduction studies characteristically show prolonged distal latencies and reduced conduction velocity, often below 38 meters per second in severely demyelinating conditions.
3. Neuronopathy — The cell body of the neuron itself is destroyed, causing length-independent deficits that do not follow the distal-to-proximal gradient typical of most polyneuropathies.
4. Vasculitic injury — Inflammation of blood vessels supplying nerves causes ischemic damage, often producing multifocal deficits consistent with multiple mononeuropathy.

In the most common form of acquired peripheral neuropathy — diabetic peripheral neuropathy — chronic hyperglycemia activates polyol and hexosamine pathways that generate oxidative stress, damaging Schwann cells and endoneural microvessels. The American Diabetes Association (ADA) estimates that diabetic peripheral neuropathy affects approximately 50 percent of people with long-standing diabetes (ADA Standards of Medical Care in Diabetes, annually updated in Diabetes Care).

The length-dependent nature of most toxic and metabolic polyneuropathies reflects the vulnerability of the longest axons. Nerve fibers extending to the feet — which may span more than 1 meter in adults — show the earliest and most severe dysfunction, producing the classic "stocking-glove" distribution of sensory loss.

Common Scenarios

Peripheral neuropathy arises from a wide range of causes, grouped by etiology:

Metabolic and systemic disease
Diabetes mellitus is the leading cause of peripheral neuropathy in the United States. Hypothyroidism, chronic kidney disease, and hepatic failure each generate distinct toxic metabolite profiles that impair axonal transport.

Toxic and drug-induced
Chemotherapy agents — particularly platinum-based drugs (cisplatin, oxaliplatin) and taxanes (paclitaxel, docetaxel) — produce chemotherapy-induced peripheral neuropathy (CIPN) in a significant portion of treated patients. The National Cancer Institute (NCI) maintains grading criteria for CIPN under the Common Terminology Criteria for Adverse Events (CTCAE), which clinicians and trial sponsors use to standardize severity reporting. Alcohol-related neuropathy, lead poisoning, and chronic nitrous oxide exposure (causing B12 inactivation) are additional toxic causes.

Infectious
Herpes zoster reactivation causes postherpetic neuralgia, a painful mononeuropathy affecting a single dermatomal distribution. HIV-associated sensory neuropathy affects an estimated 30 to 60 percent of people with HIV, according to data cited in NINDS publications. Leprosy (Mycobacterium leprae infection) remains the most common infectious cause of peripheral neuropathy globally.

Hereditary
Charcot-Marie-Tooth (CMT) disease is the most prevalent inherited peripheral neuropathy, affecting approximately 1 in 2,500 individuals (NINDS CMT information page). CMT is classified into demyelinating (CMT1) and axonal (CMT2) subtypes based on nerve conduction velocity thresholds and genetic mutation patterns.

Immune-mediated
Guillain-Barré syndrome (GBS) is an acute immune-mediated polyneuropathy with an annual incidence of approximately 1 to 2 per 100,000 population (NINDS GBS page). Chronic inflammatory demyelinating polyneuropathy (CIDP) follows a relapsing or progressive course and responds to immunotherapy, including plasma exchange and intravenous immunoglobulin — treatments discussed further at plasma exchange and IVIG.

Symptoms such as persistent numbness, tingling, or weakness in the extremities — detailed at numbness, tingling, and weakness — often represent the earliest clinical presentation warranting formal neurological evaluation.

Decision Boundaries

Accurate classification of peripheral neuropathy requires distinguishing it from conditions that mimic its presentation and from subtypes with different treatment pathways.

Peripheral neuropathy vs. radiculopathy
Radiculopathy originates at the spinal nerve root, not in peripheral nerve trunks. Its distribution follows a dermatomal pattern corresponding to a single spinal level (e.g., L5 or S1 distribution), whereas length-dependent polyneuropathy produces symmetric distal deficits. MRI of the spine (MRI brain and spine) and electrodiagnostic testing are the primary tools for differentiation.

Mononeuropathy vs. polyneuropathy
A single compressed nerve — such as the median nerve in carpal tunnel syndrome or the common peroneal nerve at the fibular head — produces focal, anatomically predictable deficits. Polyneuropathy affects nerves diffusely, typically in a length-dependent gradient. Nerve conduction studies localize the lesion site and distinguish focal entrapment from systemic disease.

Axonal vs. demyelinating polyneuropathy
This distinction carries direct therapeutic implications:

Small fiber vs. large fiber neuropathy
Standard nerve conduction studies measure large myelinated fibers (Aα and Aβ). Small fiber neuropathy — affecting unmyelinated C fibers and thinly myelinated Aδ fibers — produces burning pain, altered temperature sensation, and autonomic symptoms while yielding normal electrodiagnostic results. Skin punch biopsy with quantification of intraepidermal nerve fiber density (IENFD) is the diagnostic standard, with reference values published by normative databases and referenced in NINDS diagnostic criteria guidance.

The regulatory and clinical classification frameworks governing neurological diagnosis — including neuropathy coding, insurance criteria, and disability determination standards — are addressed at regulatory context for neurological conditions.

Patients presenting with autonomic involvement, rapid progression, or asymmetric deficits require urgent evaluation to exclude treatable causes including vasculitis, paraneoplastic syndrome, and acute demyelinating disease, all of which carry distinct management pathways distinct from the chronic length-dependent polyneuropathies that constitute the majority of outpatient cases.

References

• National Institute of Neurological Disorders and Stroke (NINDS) — Peripheral Neuropathy
• National Institute of Neurological Disorders and Stroke (NINDS) — Charcot-Marie-Tooth Disease
• [National Institute of Neurological Disorders and Stroke (NINDS) — Guillain-Barré Syndrome](https://www

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)